In November 2026 the American Cancer Society reversed a long period of caution and once again encouraged routine prostate screening, a move that reopens an old argument about when a quiet blood test is worth its risks. The change reflects a belief that the evidence has matured: the harms of follow-up can now be better managed, and the benefit of catching disease early is clearer. Yet the question lingers for men and their doctors, because other authorities still counsel more restraint, and the decision remains, as it has always been, a personal one made in conversation with a physician.
New ACS Guidelines Urge Regular Prostate Cancer Screening, Starting Earlier for High-Risk Men
Prostate cancer is the second leading cause of cancer death in American men; ACS estimates 36,320 deaths and 333,830 diagnoses in 2026.
The evidence evolved.
Mark
What actually changed here?
Mimi
The American Cancer Society went from leaving screening to individual choice, as it did in 2010, to recommending it: every two years for average-risk men aged 50 to 69, yearly from 45 for higher-risk men.
Mark
Why now?
Mimi
Advanced prostate cancer rates climbed after routine screening lost its recommendation in 2012, and the society says the evidence matured. Better follow-up, like MRI or biomarkers before biopsy, is meant to reduce unnecessary procedures.
Luke
Careful, though. "Greater certainty that screening reduces deaths" is the society's own reading, quoted from its officials. The article doesn't give the underlying trial numbers.
Mimi
True. And the climb in advanced cases is reported as following the policy change, not proven to be caused by it.
Mark
Who's most affected?
Mimi
Black men and men with a family history, who face higher risk and later-stage diagnoses. The society says begin at 45.
Luke
Yet urologist groups say 40 for those men and 45 for everyone else. So there's no single answer.
Mimi
Right, and the USPSTF still advises shared decision-making, under review since 2023.
Mark
So what should a reader take away?
Luke
That the guidelines disagree, and the article doesn't say when the task force will finish. Talk to a doctor about personal risk.
Le Pouls
- The American Cancer Society has overturned years of hesitation, urging average-risk men to test every two years from age 50 through 69.
- Higher-risk men, including Black men and those with a family history, are now advised to begin annual screening at 45.
- Doctors are weighing the fear of unnecessary biopsies and treatments against the danger of advanced disease that arrives too late.
- Competing guidance from the USPSTF, still favoring shared decision-making and under review since 2023, keeps patients receiving mixed signals.
- The trajectory points toward wider screening, but the final word awaits the federal task force's review.
In November 2026 the American Cancer Society reversed a long period of caution and once again encouraged routine prostate screening, a move that reopens an old argument about when a quiet blood test is worth its risks. The change reflects a belief that the evidence has matured: the harms of follow-up can now be better managed, and the benefit of catching disease early is clearer. Yet the question lingers for men and their doctors, because other authorities still counsel more restraint, and the decision remains, as it has always been, a personal one made in conversation with a physician.
On November 12, 2026, the American Cancer Society published a new guideline for finding prostate cancer early. For average-risk men, the recommendation is now a PSA blood test every two years from age 50 to 69. For men at higher risk, including Black men and those with a family history, testing should begin every year at 45.
The shift closes a loop that began in 2010, when the society called screening a matter for individual decision. Two years later the U.S. Preventive Services Task Force stopped recommending routine screening for all men, and in the years that followed, advanced prostate cancer rates climbed.
A high PSA reading, confirmed on repeat testing, should now lead to an MRI or a validated biomarker test before a biopsy is offered. The stakes are weighty: prostate cancer is the second leading cause of cancer death among American men, with an estimated 333,830 diagnoses and 36,320 deaths in 2026.
Julio Pow-Sang, MD, of Moffitt Cancer Center, says newer long-term data and better detection technology have changed the picture, calling the update welcome news. Shanthi Sivendran, MD, of the society, adds that the evidence has evolved enough to show that PSA screening reduces deaths and advanced disease.
The guideline eases off at the older end. Men 70 to 74 should decide with their provider, screening is not generally advised from 75, and it is not recommended for men 80 and older or those not expected to live another decade. Other bodies still differ, and until the task force completes its review, men may hear conflicting advice.
On November 12, 2026, the American Cancer Society published a new guideline for finding prostate cancer early, and with it reversed a long stretch of caution about routine screening. For men at average risk, the society now recommends a PSA blood test every two years from age 50 through 69. For men at higher risk, including Black men and men with a family history of prostate cancer, it recommends testing every year starting at age 45.
The change closes a loop that opened in 2010. That year the society said screening decisions should be made individually, in consultation with a physician. Two years later the U.S. Preventive Services Task Force stopped recommending routine screening for all men. In the years that followed, rates of advanced prostate cancer climbed.
The test itself is simple. A PSA screening measures the level of prostate-specific antigen, a substance made by the prostate that helps sperm cells stay healthy. Levels rise naturally with age, but an elevated reading can signal cancer. Under the society's guidance, a high result confirmed on repeat testing should lead to an MRI or a validated biomarker test before anyone is offered a biopsy.
The stakes are considerable. Prostate cancer is the second leading cause of cancer death among American men, behind lung cancer. The society estimates 333,830 men will be diagnosed in 2026 and 36,320 will die of the disease. Men with higher risk are more likely to be diagnosed at later stages, when the cancer is harder to treat.
Part of the earlier hesitation was a worry that screening average-risk men did more harm than good, sending them into unnecessary and invasive follow-up procedures and treatments. Julio Pow-Sang, MD, who chairs the genitourinary oncology department at Moffitt Cancer Center in Tampa, Florida, says the picture has shifted. There is now longer-term data on screening, he says, along with a better understanding of risk adjustment and better technology for detecting clinically significant cancer. He called the update welcome news with the potential to decrease prostate cancer mortality.
Shanthi Sivendran, MD, the society's interim chief patient officer, put it this way: the evidence evolved. She says there is now greater certainty that PSA screening reduces prostate cancer deaths and advanced disease, and that better ways exist to follow up an elevated PSA and to manage low-risk cancers while minimizing harms.
The guideline sets limits at the older end. Men 70 to 74 should decide with their healthcare provider whether to continue. The society does not generally recommend PSA screening from age 75, though healthy men 75 to 79 may want to continue, especially if their PSA has been rising on earlier tests. It does not recommend screening for men 80 and older, or for those not expected to live another 10 years.
Other major groups still differ. The USPSTF continues to recommend shared decision-making, guidance last updated in 2018 and listed as under review since 2023. The American Urological Association and the Society of Urologic Oncology go earlier than the cancer society: age 45 for average-risk men, and age 40 for Black men and those with a family history. Until the task force finishes its review, men may hear different advice depending on whom they ask.
Citations marquantes
The evidence evolved. We now have greater certainty that PSA screening reduces prostate cancer deaths and advanced disease.— Shanthi Sivendran, MD, interim chief patient officer, American Cancer Society
This update has the potential to decrease prostate cancer mortality.— Julio Pow-Sang, MD, Moffitt Cancer Center
Envie de l'histoire complète ?
Lire l'original sur Everyday Health ↗